KYMR · Categories · Upgrades
KYMR - Analyst upgrades
Kymera Therapeutics Inc. (KYMR) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for KYMR
- Kymera Therapeutics upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Kymera Therapeutics from Equal-Weight to Overweight and set a new price target of $79.00
- Kymera Therapeutics upgraded by B. Riley Securities with a new price targetB. Riley Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $60.00
- Kymera Therapeutics upgraded by BofA Securities with a new price targetBofA Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $51.00
- Kymera Therapeutics upgraded by Wells Fargo with a new price targetWells Fargo upgraded Kymera Therapeutics from Equal Weight to Overweight and set a new price target of $57.00
- Kymera Therapeutics upgraded by Wolfe Research with a new price targetWolfe Research upgraded Kymera Therapeutics from Peer Perform to Outperform and set a new price target of $65.00
- Kymera Therapeutics upgraded by JP MorganJP Morgan upgraded Kymera Therapeutics from Neutral to Overweight
- Kymera Therapeutics upgraded by Raymond JamesRaymond James upgraded Kymera Therapeutics from Mkt Perform to Outperform
- Kymera Therapeutics upgraded by B of A Securities with a new price targetB of A Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $80.00 from $65.00 previously